3
Indication details
- Control Arm
- Placebo
- Therapeutic Indication
- Advanced GIST 2nd line after imatinib
- Tumour Type
-
Sarcoma
- Tumour Sub-type
- GIST
- Tumour Stage
- Advanced
- NCT Number
- NCT00075218
- Trial Phase
- Phase III
Approval details
- EMA Approval
- EMA (CHMP) December 2020 EC decision February 2021
Primary Outcome(s)
- Primary Outcome(s)
- TTP (Crossover allowed)
- Evaluated Outcome
- TTP
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 6.4 weeks
- PFS Gain
- 20.9 weeks
- PFS HR
- 0.33 (0.23-0.47)
Adjustments
- QoL Comment
-
Not qualified for an ESMO-MCBS credit
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
- Comment
-
Scoring of TTP on the same basis as PFS
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 199
- Scorecard version
- 1
- Issue date
- 21.07.2020
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.